Statistics from Altmetric.com
Donepezil, a centrally acting acetylcholinesterase inhibitor, has been recently introduced for the symptomatic relief of cognitive impairment in patients with mild to moderate Alzheimer’s disease. Several adverse events thought to be related to donepezil have been reported so far, the most common ones being gastrointestinal disturbances due to cholinomimetic effects of donepezil.1Convulsions have not been reported for donepezil to date. We report on a patient with mild Alzheimer’s disease who presented with convulsions during treatment …
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.